1,796 material Form 8-K filings that 1,448 companies we cover made with the SEC in May 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
CEL-SCI Corporation sold 6,000,000 common shares at $1.20 per share under a registered offering with ThinkEquity as placement agent, for gross proceeds of approximately $7.2 million before placement fees and expenses. The offering closed on May 13, 2026, and the company plans to use the net proceeds for Multikine development, general corporate purposes and working capital. The sale adds 6,000,000 shares to the company's common stock outstanding, which dilutes existing shareholders.
6,000,000 shares sold at $1.20 per share; agreement entered May 11, 2026; offering closed May 13, 2026
Gross proceeds approximately $7.2 million, before placement agent fees and offering expenses
Placement agent cash fee of 7.0% of gross proceeds, plus expense reimbursement up to $150,000
Company agreed not to issue additional shares for 30 days from May 13, 2026; directors and officers agreed to a 45-day lock-up from May 11, 2026
Prestige Consumer Healthcare agreed to acquire LaCorium Health, an Australian skin care business, for about $150 million in cash, subject to adjustments including indebtedness. The same day it reported fiscal 2026 results showing lower revenue and lower full-year diluted EPS, alongside fiscal 2027 outlook ranges for revenue and adjusted diluted EPS that are above fiscal 2026 levels.
Sale and Purchase Deed for about $150 million in cash; closing expected in the second quarter of fiscal 2027, and either party may terminate before October 1, 2026 for an uncured breach.
Q4 fiscal 2026 revenue was $281.6 million, down 5.0% from $296.5 million; Q4 diluted EPS was $1.13 versus $1.00.
Fiscal 2026 revenue was $1,088.7 million, down 4.3%; diluted EPS was $3.91 versus $4.29, and adjusted diluted EPS was $4.38 versus $4.52.
Fiscal 2027 outlook: revenue of $1,100 million to $1,121 million, adjusted diluted EPS of $4.42 to $4.51, and free cash flow of $250 million or more.
Rapid Micro Biosystems reported first quarter 2026 total revenue of $8.0 million, up 11.1% from a year earlier, with product revenue up 36.0%. The net loss widened to $14.3 million from $11.3 million, and the company reaffirmed its full year 2026 total revenue guidance of $37.0 million to $41.0 million. For shareholders, revenue growth is offset by a larger loss and cash, short-term investments and restricted cash of about $23 million as of March 31, 2026.
Total revenue rose 11.1% to $8.0 million; product revenue rose 36.0% to $5.6 million, while service revenue fell 21.9% to $2.4 million.
Net loss was $14.3 million, or $0.31 per share, versus $11.3 million, or $0.26 per share, in the first quarter of 2025.
Full year 2026 total revenue guidance of $37.0 million to $41.0 million was reaffirmed, along with a gross margin target of approximately 20%.
Cash, short-term investments and restricted cash were about $23 million on March 31, 2026, down from $38.6 million on December 31, 2025.
Marchex reported first-quarter 2026 revenue of $10.6 million, down from $11.4 million a year earlier, while its net loss narrowed to $1.7 million from $2.0 million. The company raised its second-quarter 2026 Adjusted EBITDA guidance to $1.6 million to $1.8 million, up from prior guidance of more than $1 million, and said the proposed Archenia acquisition is expected to close in July 2026 if stockholders approve it.
Q1 2026 revenue was $10.6 million versus $11.4 million in Q1 2025.
Net loss was $1.7 million, or $(0.04) per diluted share, versus $2.0 million, or $(0.05), a year earlier.
Q2 2026 Adjusted EBITDA is now expected to be $1.6 million to $1.8 million, up from prior guidance of more than $1 million.
Marchex signed a Stock Purchase Agreement on May 8, 2026 to acquire 100% of Archenia, Inc.; closing is expected in July 2026, subject to majority approval by disinterested stockholders.
Hawkins reported fiscal 2026 sales of $1.08 billion, up 11%, but diluted earnings per share fell 3% to $3.91 and net income fell to $81.5 million from $84.3 million. The company attributed the profit decline mainly to about $16.5 million in higher amortization, interest expense and earnout-related fair value accretion from six acquisitions, and said pro forma EPS would have risen 9%. Management expects fiscal 2027 EPS to grow.
Fourth-quarter sales were $265.9 million, up 8%, while fourth-quarter diluted EPS was $0.74 versus $0.78 a year earlier.
Full-year adjusted EBITDA was $179.0 million, up 6%, and operating cash flow was $144.3 million, up 30%.
Total debt was $244.0 million at fiscal year-end, and the leverage ratio rose to 1.37x from 0.86x.
For fiscal 2027, management expects EPS to grow and an income tax rate of 25% to 27%.
Talphera reported a first quarter 2026 net loss of $2.6 million, or $0.04 per share, roughly flat in dollars from a year earlier but improved per share after a larger share count and a $1.2 million warrant liability gain. Operating expenses rose to $3.9 million from $2.9 million, and the company reported no revenue compared with $27 thousand a year earlier, so the operating loss widened. The company said NEPHRO CRRT enrollment has exceeded the 50% milestone and it expects study completion later in 2026.
Q1 2026 net loss was $2.6 million, or $0.04 per share, versus $2.6 million, or $0.10 per share, in Q1 2025
Loss from operations was $3.9 million versus $2.9 million a year earlier; revenue was zero versus $27 thousand
Cash and investments were $21.1 million at March 31, 2026, up from $20.4 million at December 31, 2025
In March 2026 the company closed a $4.1 million third tranche of its March 2025 private placement after reaching the 35-patient enrollment milestone
Doximity reported fiscal fourth-quarter 2026 revenue of $145.4 million, up 5%, but GAAP net income fell to $19.1 million from $62.5 million and adjusted EBITDA declined 6%. The company also gave fiscal 2027 revenue guidance of $664 million to $676 million and named Matthew Sonefeldt as chief financial officer and Steven L. Zatz, M.D. as president, both effective May 13, 2026.
Q4 revenue $145.4 million vs. $138.3 million; net income $19.1 million vs. $62.5 million; diluted EPS $0.10 vs. $0.31
Q4 adjusted EBITDA $65.8 million vs. $69.7 million; full-year fiscal 2026 revenue $644.9 million, up 13%
Fiscal 2027 guidance: revenue $664 million to $676 million; adjusted EBITDA $323 million to $335 million; fiscal Q1 revenue $151 million to $152 million
Matthew Sonefeldt becomes principal financial officer June 8, 2026; Siddharth Sitaram serves as interim PFO through June 7, 2026
Grocery Outlet reported a first-quarter fiscal 2026 net loss of $180.3 million, or $(1.83) per diluted share, compared with a net loss of $23.3 million, or $(0.24), a year earlier. The loss reflects a $158.0 million non-cash goodwill impairment, while net sales rose 3.6% to $1.17 billion, and the company reaffirmed its fiscal 2026 guidance. For shareholders, sales growth was offset by a sharp decline in profit and a much larger per-share loss.
Net sales rose 3.6% to $1.17 billion, but comparable store sales declined 1.0%.
Net loss was $180.3 million, or $(1.83) per diluted share, versus $23.3 million, or $(0.24), a year earlier, including the $158.0 million goodwill impairment.
Adjusted EBITDA was $43.1 million, or 3.7% of net sales, compared with $51.9 million, or 4.6%, last year.
Fiscal 2026 guidance was reaffirmed, including adjusted EBITDA of $220 million to $235 million and diluted adjusted EPS of $0.45 to $0.55.
Neonode reported results for the quarter ended March 31, 2026. Revenue from continuing operations rose 19.7% to $0.6 million, driven by new license agreements, while operating expenses rose 8.6% to $2.7 million, mainly from higher professional fees. The loss from continuing operations widened to $1.9 million, or $0.11 per share, from $1.8 million, or $0.11 per share, a year earlier.
Revenue from continuing operations was $0.6 million, up 19.7% from the prior-year quarter.
Loss from continuing operations was $1.9 million, or $0.11 per share, compared with $1.8 million, or $0.11 per share, a year earlier.
Cash used in operations was $2.1 million, compared with $1.4 million a year earlier.
Cash and accounts receivable totaled $23.8 million at March 31, 2026, down from $25.8 million at December 31, 2025.
Bloomia Holdings reported results for the three and nine months ended March 31, 2026, in a press release furnished as Exhibit 99.1 to a Form 8-K. Third-quarter net revenue rose to $14.4 million from $12.4 million, but the company posted a net loss attributable to Bloomia Holdings of $0.8 million, or $0.43 per diluted share, compared with net income of $0.4 million, or $0.25 per share, a year earlier. For the nine months, the loss attributable to the company widened to $5.9 million, or $3.33 per share, and management cited rising raw material costs, tariffs and currency pressure.
Q3 net revenue was $14.4 million vs. $12.4 million a year earlier; gross margin was 19.8% vs. 31.3%.
Q3 net loss attributable to Bloomia Holdings was $0.8 million, or $0.43 per diluted share, vs. net income of $0.4 million, or $0.25 per share.
Nine-month net loss attributable to Bloomia Holdings was $5.9 million, or $3.33 per share, vs. $3.6 million, or $2.04 per share; cash used in operations was $11.1 million.
Rights offering expired April 1, 2026, with gross proceeds of $12.1 million at $4.05 per share, including $7.1 million from conversion of debt.
Xtant Medical reported first-quarter 2026 revenue of $20.9 million, down from $32.9 million a year earlier, and a net loss of $3.1 million, compared with net income of $58,000. The company raised its full-year 2026 revenue guidance to $101 million to $105 million from $95 million to $99 million, citing its exclusive U.S. distribution agreement for Dilon Technologies' HEMOBLAST Bellows product. Revenue and profit declined while guidance rose, so the results point in mixed directions for shareholders.
Q1 2026 revenue was $20.9 million versus $32.9 million in Q1 2025, mainly due to the Companion Spine asset sale and 2025 license revenue that did not repeat.
Q1 2026 net loss was $3.1 million versus net income of $58,000; non-GAAP adjusted EBITDA was a loss of $1.6 million versus positive $3.0 million.
2026 revenue guidance raised to $101 million to $105 million from $95 million to $99 million, tied to the Dilon Technologies HEMOBLAST Bellows agreement.
Total indebtedness fell $13.3 million in Q1 2026; cash and cash equivalents were $12.2 million as of March 31, 2026.
Dynatrace reported fourth-quarter and full-year fiscal 2026 results, with quarterly revenue up 19% and ARR up 18%, while GAAP net income fell to $17 million from $39 million a year earlier. The company also issued fiscal 2027 guidance for total revenue of $2,317 million to $2,335 million and non-GAAP earnings per diluted share of $1.93 to $1.95, and it spent $224 million on share repurchases in the quarter.
Q4 total revenue was $532 million, up 19%, and total ARR was $2,054 million, up 18%.
Q4 GAAP net income was $17 million, or $0.06 per diluted share, versus $39 million, or $0.13, a year earlier; GAAP results included an $18.5 million impairment of long-lived assets.
Q4 non-GAAP net income per diluted share was $0.41, up from $0.33.
Fiscal 2027 guidance: total revenue of $2,317 million to $2,335 million and non-GAAP net income per diluted share of $1.93 to $1.95.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.